These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 15321996)

  • 1. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].
    Shaper M; Hollingshead SK; Benjamin WH; Briles DE
    Infect Immun; 2004 Sep; 72(9):5031-40. PubMed ID: 15321996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of lactoferrin and lysozyme on Streptococcus pneumoniae killing.
    André GO; Politano WR; Mirza S; Converso TR; Ferraz LF; Leite LC; Darrieux M
    Microb Pathog; 2015 Dec; 89():7-17. PubMed ID: 26298002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of differences in pspA alleles and capsular types on the resistance of Streptococcus pneumoniae to killing by apolactoferrin.
    Mirza S; Benjamin WH; Coan PA; Hwang SA; Winslett AK; Yother J; Hollingshead SK; Fujihashi K; Briles DE
    Microb Pathog; 2016 Oct; 99():209-219. PubMed ID: 27569531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin.
    Mirza S; Wilson L; Benjamin WH; Novak J; Barnes S; Hollingshead SK; Briles DE
    Infect Immun; 2011 Jun; 79(6):2440-50. PubMed ID: 21422179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal surface protein A (PspA) prevents killing of Streptococcus pneumoniae by indolicidin.
    Waz NT; Milani B; Assoni L; Coelho GR; Sciani JM; Parisotto T; Ferraz LFC; Hakansson AP; Converso TR; Darrieux M
    Sci Rep; 2024 Oct; 14(1):23517. PubMed ID: 39384882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae.
    Daniels CC; Briles TC; Mirza S; Håkansson AP; Briles DE
    Microb Pathog; 2006 May; 40(5):228-33. PubMed ID: 16540281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a modified opsonophagocytic killing assay for anti-pneumococcal surface protein A antibody.
    Kuroda E; Koizumi Y; Piao Z; Nakayama H; Tomono K; Oishi K; Hamaguchi S; Akeda Y
    J Microbiol Methods; 2023 Sep; 212():106804. PubMed ID: 37543109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).
    Genschmer KR; Accavitti-Loper MA; Briles DE
    Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA.
    Genschmer KR; Vadesilho CFM; McDaniel LS; Park SS; Hale Y; Miyaji EN; Briles DE
    mSphere; 2019 Dec; 4(6):. PubMed ID: 31826968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.
    Daniels CC; Coan P; King J; Hale J; Benton KA; Briles DE; Hollingshead SK
    Infect Immun; 2010 May; 78(5):2163-72. PubMed ID: 20194601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia.
    Brooks-Walter A; Briles DE; Hollingshead SK
    Infect Immun; 1999 Dec; 67(12):6533-42. PubMed ID: 10569772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein a provides insight into microbial defense mechanism.
    Senkovich O; Cook WJ; Mirza S; Hollingshead SK; Protasevich II; Briles DE; Chattopadhyay D
    J Mol Biol; 2007 Jul; 370(4):701-13. PubMed ID: 17543335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of binding of human lactoferrin to pneumococcal surface protein A.
    Håkansson A; Roche H; Mirza S; McDaniel LS; Brooks-Walter A; Briles DE
    Infect Immun; 2001 May; 69(5):3372-81. PubMed ID: 11292760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PspA facilitates evasion of pneumococci from bactericidal activity of neutrophil extracellular traps (NETs).
    Martinez PJ; Farhan A; Mustafa M; Javaid N; Darkoh C; Garrido-Sanabria E; Fisher-Hoch SP; Briles DE; Kantarci A; Mirza S
    Microb Pathog; 2019 Nov; 136():103653. PubMed ID: 31398527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Streptococcus pneumoniae Binds to Host Lactate Dehydrogenase via PspA and PspC To Enhance Virulence.
    Park SS; Gonzalez-Juarbe N; Martínez E; Hale JY; Lin YH; Huffines JT; Kruckow KL; Briles DE; Orihuela CJ
    mBio; 2021 May; 12(3):. PubMed ID: 33947761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.
    Ren B; Szalai AJ; Thomas O; Hollingshead SK; Briles DE
    Infect Immun; 2003 Jan; 71(1):75-85. PubMed ID: 12496151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model.
    Roche H; Håkansson A; Hollingshead SK; Briles DE
    Infect Immun; 2003 Mar; 71(3):1033-41. PubMed ID: 12595413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.
    McDaniel LS; Sheffield JS; Delucchi P; Briles DE
    Infect Immun; 1991 Jan; 59(1):222-8. PubMed ID: 1987036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.